Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $13.6 million.

  • Anika Therapeutics' Accumulated Expenses fell 23.18% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 23.18%. This contributed to the annual value of $13.6 million for FY2024, which is 3.55% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Accumulated Expenses is $13.6 million, which was down 3.55% from $14.1 million recorded in FY2023.
  • Anika Therapeutics' Accumulated Expenses' 5-year high stood at $18.8 million during FY2022, with a 5-year trough of $13.6 million in FY2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $14.1 million (2023), whereas its average is $15.5 million.
  • In the last 5 years, Anika Therapeutics' Accumulated Expenses increased by 20.64% in 2021 and then dropped by 25.34% in 2023.
  • Anika Therapeutics' Accumulated Expenses (Yearly) stood at $14.8 million in 2020, then rose by 20.64% to $17.8 million in 2021, then rose by 5.56% to $18.8 million in 2022, then dropped by 25.34% to $14.1 million in 2023, then dropped by 3.55% to $13.6 million in 2024.